SG11201703322UA - Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers - Google Patents
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancersInfo
- Publication number
- SG11201703322UA SG11201703322UA SG11201703322UA SG11201703322UA SG11201703322UA SG 11201703322U A SG11201703322U A SG 11201703322UA SG 11201703322U A SG11201703322U A SG 11201703322UA SG 11201703322U A SG11201703322U A SG 11201703322UA SG 11201703322U A SG11201703322U A SG 11201703322UA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- hcc
- cancers
- combination
- hepatocellular carcinoma
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 title 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096165P | 2014-12-23 | 2014-12-23 | |
GB201423016 | 2014-12-23 | ||
GBGB1501017.6A GB201501017D0 (en) | 2014-12-23 | 2015-01-21 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
PCT/EP2015/080018 WO2016102272A1 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703322UA true SG11201703322UA (en) | 2017-07-28 |
Family
ID=52630910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703322UA SG11201703322UA (en) | 2014-12-23 | 2015-12-16 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
Country Status (25)
Country | Link |
---|---|
US (8) | US10064926B2 (fr) |
EP (8) | EP3545965B1 (fr) |
JP (2) | JP6906156B2 (fr) |
KR (1) | KR102284493B1 (fr) |
CN (4) | CN112646021A (fr) |
AR (2) | AR103220A1 (fr) |
AU (3) | AU2015371490B2 (fr) |
BR (1) | BR112017008972A2 (fr) |
CA (1) | CA2972126A1 (fr) |
CL (1) | CL2017001391A1 (fr) |
CR (1) | CR20170282A (fr) |
DK (4) | DK3616706T3 (fr) |
EA (2) | EA201791150A1 (fr) |
GB (1) | GB201501017D0 (fr) |
IL (1) | IL250989B (fr) |
MA (3) | MA40136A1 (fr) |
MX (1) | MX2017008329A (fr) |
PE (1) | PE20170940A1 (fr) |
PH (1) | PH12017500484A1 (fr) |
PL (1) | PL3236985T5 (fr) |
RS (4) | RS59836B2 (fr) |
SG (1) | SG11201703322UA (fr) |
SI (3) | SI3626729T1 (fr) |
TW (1) | TWI687436B (fr) |
WO (1) | WO2016102272A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
EP3092049A1 (fr) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Dispositif d'acoustophorèse avec double chambre acoustophorétique |
WO2015164826A2 (fr) * | 2014-04-24 | 2015-10-29 | Rhode Island Hospital | Induction par l'aspartate-ss-hydroxylase d'une réponse des cellules t spécifique des épitopes dans les tumeurs |
US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
HUE056607T2 (hu) | 2014-12-23 | 2022-02-28 | Immatics Biotechnologies Gmbh | Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra |
MY186837A (en) | 2014-12-23 | 2021-08-25 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
JP2019524872A (ja) | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
CN109906224B (zh) | 2016-06-20 | 2022-02-25 | 诺华股份有限公司 | 三唑吡啶化合物及其应用 |
RU2754856C2 (ru) | 2016-06-20 | 2021-09-08 | Новартис Аг | Кристаллические формы соединения триазолопиримидина |
AU2017341112B2 (en) * | 2016-10-07 | 2024-06-27 | Io Biotech Aps | Immunogenic arginase peptides |
JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス, インク.Flodesign Sonics, Inc. | 音響による親和性細胞抽出 |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
EP4035675A3 (fr) * | 2017-01-27 | 2022-11-16 | Immatics Biotechnologies GmbH | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
EP3638695A4 (fr) * | 2017-06-14 | 2021-06-30 | Icahn School of Medicine at Mount Sinai | Procédés pour la détection et le traitement de classes de carcinome hépatocellulaire sensible à une immunothérapie |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
DK3428194T3 (da) | 2017-07-14 | 2021-11-15 | Immatics Biotechnologies Gmbh | Forbedret polypeptidmolekyle med dobbelt specificitet |
WO2019030311A1 (fr) * | 2017-08-09 | 2019-02-14 | Pamgene Bv | Méthode de prédiction de la réponse de patients atteints d'un carcinome du poumon non à petites cellules à un médicament |
GB201713700D0 (en) * | 2017-08-25 | 2017-10-11 | Anastasis Biotec Ltd | Peptide conjugates |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
EP3765071A4 (fr) * | 2018-03-12 | 2022-05-25 | The Children's Hospital of Philadelphia | Procédés et compositions pour l'utilisation d'auto-antigènes tumoraux en immunothérapie adoptive |
DE102018122546B3 (de) * | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
CN113286876A (zh) * | 2018-10-26 | 2021-08-20 | T·巴尔 | 用于生物降解酒精的组合物和方法 |
CN109663128A (zh) * | 2018-11-21 | 2019-04-23 | 中国农业大学 | 一种肺动脉高压标志物及其作为治疗靶点的应用 |
US20220054614A1 (en) * | 2018-12-13 | 2022-02-24 | Rhode Island Hospital | Inhibition of asph expressing tumor growth and progression |
EP3721899A1 (fr) | 2019-04-08 | 2020-10-14 | China Medical University | Polythérapies comprenant un vaccin basé sur des cellules dendritiques et inhibiteur de point de contrôle immunitaire |
CN110850086B (zh) * | 2019-11-18 | 2023-05-02 | 西安交通大学 | 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用 |
CN113388024A (zh) * | 2020-03-18 | 2021-09-14 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
WO2021201526A1 (fr) * | 2020-03-30 | 2021-10-07 | 주식회사 로펠바이오 | Biomarqueur pour l'immunothérapie contre le cancer et son utilisation |
EP4153633A1 (fr) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Constructions de liaison à mageb2 |
CN112063718A (zh) * | 2020-09-18 | 2020-12-11 | 中国医科大学 | Usp14在肝细胞肝癌诊断、预后判断以及治疗中的应用 |
CN112043722B (zh) * | 2020-09-25 | 2022-02-15 | 中国医科大学 | Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用 |
CN114574486B (zh) * | 2020-12-01 | 2024-04-16 | 中国科学院大连化学物理研究所 | 作用于OPLAH的siRNA、DNA及构建物和应用 |
AU2022246675A1 (en) | 2021-04-02 | 2023-10-19 | Amgen Inc. | Mageb2 binding constructs |
AU2022314744A1 (en) * | 2021-07-19 | 2024-02-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Mct11 antibodies to treat t cell functional exhaustion and enhance cancer immunotherapy |
CN113502300B (zh) * | 2021-07-21 | 2024-02-06 | 徐州医科大学 | 一种含有hdac10基因启动子序列和报告基因的重组质粒、制备方法及应用 |
CN115572764B (zh) * | 2022-03-30 | 2024-06-21 | 江苏鹍远生物技术有限公司 | 一组肿瘤检测标志物及其用途 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
NZ192465A (en) | 1978-12-22 | 1983-09-30 | Biogen Nv | Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AU2061201A (en) * | 1999-12-17 | 2001-06-25 | Chiron Corporation | Mammalian dishevelled-associated proteins |
EP1259601A2 (fr) | 2000-02-22 | 2002-11-27 | Ahuva Nissim | Banques d'affichage de phages chimeriques et tcr, reactifs chimeriques et tcr et methodes d'utilisation correspondantes |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
CA2404489A1 (fr) | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Complexes majeurs d'histocompatibilite monocatenaires de classe 1, constructions les codant et leurs methodes de production |
CA2411470C (fr) | 2000-06-05 | 2020-05-05 | Sunol Molecular Corporation | Fusions et conjugues de recepteurs de lymphocytes t et procedes d'utilisation correspondants |
AU2001276018A1 (en) | 2000-07-20 | 2002-02-05 | Regents Of The University Of Minnesota | Radiolabeled immunotoxins |
US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
EP1485075A4 (fr) | 2002-02-20 | 2006-04-26 | Dyax Corp | Ligands de liaison au complexe mhc-peptide |
US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
AU2003254950A1 (en) * | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
CA2505558C (fr) | 2002-11-09 | 2013-07-02 | Avidex Limited | Presentation de recepteurs pour l'antigene des lymphocytes t |
US20040096982A1 (en) | 2002-11-19 | 2004-05-20 | International Business Machines Corporation | Methods and apparatus for analysis of mass spectra |
DE602004015064D1 (de) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090075304A1 (en) | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
ATE440107T1 (de) | 2005-09-05 | 2009-09-15 | Immatics Biotechnologies Gmbh | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe |
ATE461214T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
EP2057465A4 (fr) | 2006-08-09 | 2010-04-21 | Homestead Clinical Corp | Protéines spécifiques d'organes et procédés d'utilisation |
UA103882C2 (uk) * | 2007-07-27 | 2013-12-10 | Імматікс Біотекнолоджіс Гмбх | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина |
KR101290892B1 (ko) * | 2007-07-27 | 2013-07-31 | 이매틱스 바이오테크놀로지스 게엠베하 | 신경 및 뇌 종양에 대한 신규 면역요법 |
WO2009026547A1 (fr) | 2007-08-22 | 2009-02-26 | Receptor Logi, Ltd. | Procédés d'analyse de l'activité de vaccin |
HUE029164T2 (hu) * | 2007-09-14 | 2017-02-28 | Univ Brussel Vrije | Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra |
WO2009108372A2 (fr) * | 2008-02-27 | 2009-09-03 | Receptor Logic, Inc. | Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation |
DK2105501T3 (da) * | 2008-03-27 | 2015-11-23 | Immatics Biotechnologies Gmbh | Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer |
US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
WO2009151487A1 (fr) * | 2008-06-13 | 2009-12-17 | Receptor Logic, Inc. | Procédés de dosage de la puissance d’un vaccin |
DE102008049136B4 (de) | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
EP2499488A1 (fr) | 2009-11-14 | 2012-09-19 | Kuang-Yuh Chyu | Procédés et systèmes d'immunomodulation pour le traitement et/ou la prévention de l'athérosclérose |
US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
US20140170168A1 (en) | 2010-10-26 | 2014-06-19 | Yoram Reiter | Antibodies which bind soluble t-cell receptor ligands |
EP2637689A2 (fr) | 2010-11-12 | 2013-09-18 | Cedars-Sinai Medical Center | Procédés et systèmes immunomodulateurs pour le traitement et/ou la prévention de l'hypertension |
CN103501806A (zh) | 2010-11-12 | 2014-01-08 | 赛达斯西奈医疗中心 | 用于治疗和/或预防动脉瘤的免疫调节方法和系统 |
US20130302362A1 (en) | 2010-11-12 | 2013-11-14 | Cedars-Sinai Medical Center | Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100 |
WO2013057586A1 (fr) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions et procédés de production de récepteurs solubles des lymphocytes t |
EP2788012A4 (fr) * | 2011-11-11 | 2015-08-05 | Cedars Sinai Medical Center | Compositions et méthodes de traitement de maladies rénales |
GB201208293D0 (en) * | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
US10682399B2 (en) * | 2012-09-05 | 2020-06-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
EP2917388B1 (fr) | 2012-11-08 | 2016-10-05 | Roche Diagnostics GmbH | Acides nucléiques codant pour des polypeptides chimériques pour criblage de banque |
GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
US9134326B2 (en) * | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
EP2808392A1 (fr) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer |
CN103739667B (zh) * | 2013-09-24 | 2017-08-25 | 上海宇研生物技术有限公司 | 卵巢癌特异的肿瘤抗原肽及其制备方法 |
KR102290829B1 (ko) | 2014-03-14 | 2021-08-18 | 이뮤노코어 리미티드 | Tcr 라이브러리 |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
SI3440106T1 (sl) | 2016-04-08 | 2022-02-28 | Adaptimmune Limited | T-celični receptorji |
BR112018070637A2 (pt) | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
CA3020530A1 (fr) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | Recepteurs de lymphocytes t |
WO2018022573A1 (fr) | 2016-07-27 | 2018-02-01 | Sharp Laboratories Of America, Inc. | Procédés et appareil de télécommunication sans fil utilisant une étiquette de valeur d'information système |
WO2018140525A1 (fr) | 2017-01-24 | 2018-08-02 | Abexxa Biologics, Inc. | Méthodes et compositions destinées à cibler un complexe comprenant un hla-i non classique et un néo-antigène dans le traitement du cancer |
US20200325244A1 (en) | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
JP7202512B2 (ja) | 2017-06-05 | 2023-01-12 | 国立大学法人三重大学 | Mage-a4由来ペプチドを認識する抗原結合性タンパク質 |
CA3066932A1 (fr) | 2017-07-04 | 2019-01-10 | Curevac Ag | Nouvelles molecules d'acide nucleique |
EP3668539A4 (fr) | 2017-08-18 | 2021-08-18 | Gritstone Oncology, Inc. | Protéines de liaison d'antigène ciblant des antigènes partagés |
WO2019051001A1 (fr) | 2017-09-06 | 2019-03-14 | California Institute Of Technology | Signalisation et récepteurs bifonctionnels présentant des antigènes (sabr) |
CN111886027A (zh) | 2017-12-28 | 2020-11-03 | 磨石肿瘤生物技术公司 | 靶向共同抗原的抗原结合蛋白 |
EP3784255A4 (fr) | 2018-04-19 | 2022-06-22 | Board of Regents, The University of Texas System | Récepteurs de lymphocytes t spécifiques de mage-b2 et leurs utilisations |
TW202000907A (zh) | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 共有抗原 |
US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
US20200291127A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
US20200291116A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
-
2015
- 2015-01-21 GB GBGB1501017.6A patent/GB201501017D0/en not_active Ceased
- 2015-12-16 EA EA201791150A patent/EA201791150A1/ru unknown
- 2015-12-16 JP JP2017518096A patent/JP6906156B2/ja active Active
- 2015-12-16 DK DK19199098.5T patent/DK3616706T3/da active
- 2015-12-16 BR BR112017008972-6A patent/BR112017008972A2/pt active Search and Examination
- 2015-12-16 EP EP19170191.1A patent/EP3545965B1/fr active Active
- 2015-12-16 CN CN202011432405.4A patent/CN112646021A/zh active Pending
- 2015-12-16 SI SI201531721T patent/SI3626729T1/sl unknown
- 2015-12-16 MX MX2017008329A patent/MX2017008329A/es active IP Right Grant
- 2015-12-16 PE PE2017000542A patent/PE20170940A1/es unknown
- 2015-12-16 WO PCT/EP2015/080018 patent/WO2016102272A1/fr active Application Filing
- 2015-12-16 EP EP19199106.6A patent/EP3626730A1/fr not_active Withdrawn
- 2015-12-16 KR KR1020177017192A patent/KR102284493B1/ko active IP Right Grant
- 2015-12-16 CA CA2972126A patent/CA2972126A1/fr active Pending
- 2015-12-16 EP EP19199125.6A patent/EP3626731B1/fr active Active
- 2015-12-16 EA EA202190587A patent/EA202190587A3/ru unknown
- 2015-12-16 EP EP19199098.5A patent/EP3616706B1/fr active Active
- 2015-12-16 EP EP19199114.0A patent/EP3620168A1/fr not_active Withdrawn
- 2015-12-16 EP EP20172206.3A patent/EP3715357A1/fr active Pending
- 2015-12-16 SI SI201531682T patent/SI3545965T1/sl unknown
- 2015-12-16 CN CN201580055141.6A patent/CN107001414A/zh active Pending
- 2015-12-16 RS RS20191606A patent/RS59836B2/sr unknown
- 2015-12-16 RS RS20211033A patent/RS62237B1/sr unknown
- 2015-12-16 RS RS20211341A patent/RS62508B1/sr unknown
- 2015-12-16 PL PL15813809.9T patent/PL3236985T5/pl unknown
- 2015-12-16 MA MA40136A patent/MA40136A1/fr unknown
- 2015-12-16 DK DK19199101.7T patent/DK3626729T3/da active
- 2015-12-16 SI SI201531025T patent/SI3236985T2/sl unknown
- 2015-12-16 SG SG11201703322UA patent/SG11201703322UA/en unknown
- 2015-12-16 DK DK19199125.6T patent/DK3626731T3/da active
- 2015-12-16 EP EP15813809.9A patent/EP3236985B2/fr active Active
- 2015-12-16 DK DK19170191.1T patent/DK3545965T3/da active
- 2015-12-16 AU AU2015371490A patent/AU2015371490B2/en not_active Ceased
- 2015-12-16 MA MA41237A patent/MA41237B1/fr unknown
- 2015-12-16 RS RS20211276A patent/RS62448B1/sr unknown
- 2015-12-16 CR CR20170282A patent/CR20170282A/es unknown
- 2015-12-16 CN CN202011429041.4A patent/CN112538109A/zh active Pending
- 2015-12-16 MA MA49158A patent/MA49158B1/fr unknown
- 2015-12-16 EP EP19199101.7A patent/EP3626729B1/fr active Active
- 2015-12-16 CN CN202011429073.4A patent/CN112646025A/zh active Pending
- 2015-12-21 TW TW104142988A patent/TWI687436B/zh active
- 2015-12-21 US US14/975,952 patent/US10064926B2/en active Active
- 2015-12-21 AR ARP150104228A patent/AR103220A1/es unknown
-
2016
- 2016-11-21 US US15/357,757 patent/US20170080070A1/en not_active Abandoned
-
2017
- 2017-03-07 IL IL250989A patent/IL250989B/en active IP Right Grant
- 2017-03-14 PH PH12017500484A patent/PH12017500484A1/en unknown
- 2017-05-31 CL CL2017001391A patent/CL2017001391A1/es unknown
-
2018
- 2018-03-09 US US15/917,098 patent/US20180207252A1/en not_active Abandoned
- 2018-03-12 US US15/918,788 patent/US11406693B2/en active Active
- 2018-09-18 US US16/134,422 patent/US20190000947A1/en not_active Abandoned
-
2020
- 2020-06-29 US US16/915,308 patent/US20200376103A1/en not_active Abandoned
- 2020-08-04 AU AU2020213295A patent/AU2020213295B2/en not_active Ceased
- 2020-08-04 AU AU2020213294A patent/AU2020213294B2/en active Active
- 2020-09-11 US US17/018,915 patent/US20200405831A1/en not_active Abandoned
-
2021
- 2021-03-26 JP JP2021052978A patent/JP2021104033A/ja active Pending
- 2021-04-30 US US17/245,918 patent/US11786583B2/en active Active
- 2021-07-14 AR ARP210101973A patent/AR122964A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250989A0 (en) | New peptides and a combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other types of cancer | |
SG10202101368WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
GB201511792D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers | |
GB201505305D0 (en) | Novel Peptides and combination of peptides for use in immunotherapy against various tumors | |
HK1246181A1 (zh) | 用於各種腫瘤免疫治療的新型肽和肽組合物 | |
HK1255541A1 (zh) | 用於多種癌症免疫治療的新型肽和肽組合物 | |
IL281752A (en) | New peptides and combinations of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |